Dove Medical Press podcasts

Professor Arschang Valipour is this week’s expert guest on the Medical Insider COPD podcast. Join him and Dr Richard Russell as they discuss the role of phenotyping in patients with COPD and how it could influence management decisions. 1,2 A new publication on the use of low-dose morphine for chronic breathlessness will be discussed by Dr Russell,3 alongside the effects of winter weather on respiratory disease, which has been a hot topic on social media this week. Stay tuned for more exciting topics on the Medical Insider COPD podcast!
1 Bakeer M, et al. Ann Transl Med 2020;8:1472;2 Koblizek V, et al. Eur Respir J 2017;49:1601556;3 Currow D, et al. Respir Res 2020;75:50–56.
DisclosuresProfessor Arschang ValipourProfessor Valipour reports speaker and/or consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis and Pulmonx.
Bios:
Professor Arschang ValipourProfessor Arschang Valipour is Head of the Department of Respiratory and Critical Care Medicine at Klinik Floridsdorf and Research Director of the Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, Austria. Dr Valipour was appointed Associate Professor in Pulmonology at that university in 2010. Dr Valipour serves on multiple advisory and data safety monitoring boards and coordinates research as the Principal Investigator of clinical trials in the field of COPD, COVID-19 and Lung Cancer. He is Fellow of the European Respiratory Society (FERS), member of the European Respiratory Society (ERS) College of Experts, and previously served as a Secretary to the Sleep and Breathing Working Group of the ERS.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Epidemiology and comorbidities in COPD will be thoroughly discussed on this week's episode of the Medical Insider COPD podcast, as Dr Richard Russell is joined by Professor Jennifer Quint. They will discuss the differences between COPD populations in randomised controlled trials and real-world observational studies,1,2 as well as the importance of treating cardiovascular comorbidities in people with COPD.3 Dr Russell will then talk through the most important takeaways from a recent publication on exacerbations and muscle loss in smokers with COPD.4 Finally, he will discuss biomass fuels and their effect on people with respiratory disorders, which has been a hot topic on social media this week.
1 Quint JK, et al. Adv Ther 2021; https://doi.org/10.1007/s12325-021-01646-5;2 Rabe KF, et al. N Engl J Med 2020;383:35–48; 3 Axson EL, et al. Thorax 2021; ISSN:0040-6376;4 Mason SE, et al. Thorax 2021; doi: https://doi.org/10.1136/thoraxjnl-2020-215999. Online ahead of print.
DisclosuresProfessor Jennifer QuintProfessor Quint has received grants from Asthma UK, AstraZeneca, Bayer, Boehringer Ingelheim, British Lung Foundation, Chiesi, The Health Foundation, GlaxoSmithKline, Insmed, IQVIA and MRC, and personal fees for advisory board participation or speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim and GlaxoSmithKline.
Bios:
Professor Jennifer QuintProfessor Jennifer Quint (MSc PhD FHEA FRCP) is a Professor of Respiratory Epidemiology at the National Heart and Lung Institute, Imperial College London, and an Honorary Respiratory Consultant. She leads a clinical epidemiology research group whose work centres largely on understanding the relationship between cardiovascular and respiratory disease as well as maximising the quality, linkage and usage of routinely collected data for clinical and research purposes. She partners with the Royal College of Physicians, is Analysis Lead for the National Asthma and COPD Audit Programme and is the Deputy Director of the BREATHE HDR UK hub. She currently serves as an Associate Editor for Thorax and is the Information Governance Trustee for the British Thoracic Society.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This episode of the Medical Insider COPD podcast starts with Dr Richard Russell and Dr Marc Miravitlles as they discuss the role of inhaled corticosteroids (ICS) in COPD treatment. Listen as they describe which subgroups of patients with COPD are most likely to benefit from ICS and what clinical studies into dual bronchodilation vs. ICS reveal.1–3 Dr Russell will follow this by discussing key takeaways from a new publication on the prevalence of pulmonary embolism in patients hospitalised with COPD,4 and by talking to us about a social media hot topic – singing and COPD. Keep an eye out for future episodes of the Medical Insider COPD podcast!
1Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available at: here. Last accessed: November 2021;2Brusselle G, et al. Int J Chron Obstruct Pulmon Dis 2015;10:2207–2217;3Stolz D & Miravitlles M. Eur Respir J 2020;55:2000881;4Couturaud F, et al. JAMA 2021;325:59–68
DisclosuresDr Marc MiravitllesDr Marc Miravitlles has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Grifols, Menarini, Novartis, Rovi, Sandoz and Zambon. He reports consulting fees from AstraZeneca, Atriva Therapeutics, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Inhibrx, Laboratorios Esteve, Mereo Biopharma, Novartis, ONO Pharma, Palobiofarma, pH Pharma, Sanofi, SL Spin Therapeutics, Takeda, and Verona Pharma, and research grants from Grifols. 
Bios:
Dr Marc MiravitllesDr Marc Miravitlles is a Senior Researcher and Consultant at Vall d’Hebron University Hospital, Barcelona, Spain. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines on COPD, including the American Thoracic Society and ERS guidelines on exacerbations of COPD. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD and the coordinator of the Spanish National Guidelines for COPD.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Professor Jodie Simpson joins Dr Richard Russell on the Medical Insider COPD podcast this week to discuss the management of airway inflammation in COPD. Listen as she explains the different types of airway inflammation and discusses the role of macrolides in COPD patient treatment.1–3 Dr Russell will then review an important recent publication on the effect of muscarinic antagonists on airway inflammation.4 As this week’s social media hot topic, he will be highlighting what patients with COPD think of the COVID-19 vaccination programme. Don’t miss out on new content, directly from the source to you!
1Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 20212Simpson JL. Respirology 2020;25:47–483Simpson JL, et al. Respirology 2016;21:697–7044Calzetta L, et al. Int J Chron Obstruct Pulmon Dis 2021;16:257–279
DisclosuresProfessor Jodie SimpsonProfessor Jodie Simpson has no disclosures.
Bios:
Professor Jodie SimpsonProfessor Jodie Simpson (FThorSoc FERS) is the Deputy Director of the University of Newcastle's Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, at the University of Newcastle, Australia. Jodie's work has significantly advanced the understanding of asthma, pathogenesis and therapeutic approaches. Her current research focuses on understanding the mechanisms of inflammation in asthma and COPD, and specifically on the role of airway phagocytes and bacterial colonisation. This work is complemented by her research investigating macrolide antibiotics as an anti-inflammatory therapy in asthma and COPD.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Professor Jill Ohar joins Dr Richard Russell for this episode to discuss the management of COPD during the COVID-19 pandemic. Listen as they explore the impact of lockdown on COPD outcomes,1–3 which treatments should be used and how we can continue to improve our use of telemedicine in the future. Following this, Dr Russell will explain the key findings and takeaways from a publication on the risk of acquired Pseudomonas with inhaled corticosteroid use,4 before taking us through this week’s social media hot topic of COPD communities during the pandemic. Keep an eye out for future episodes of Season 3 of the Medical Insider COPD podcast!
1 Alqahtani JS, et al. PLoS One 2021;16:e0255659; 2 Hingham A, et al. Eur Respir Rev 2020;29:200199; 3 Hume E, et al. Breathe 2020;16:200231; 4 Eklöf J, et al. Thorax 2021; doi: https://doi.org/10.1136/thoraxjnl-2021-217160.
DisclosuresProfessor Jill OharProfessor Jill Ohar reports grants from Boehringer Ingelheim, Sunovion and Teva. She reports advisory board fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Reckitt Benckiser, Sunovion, Teva, Theravance and Verona.
Bios:
Professor Jill OharJill Ohar is a tenured professor at the Wake Forest School of Medicine, North Carolina, USA, and has served on the faculty at Saint Louis University, Missouri, USA. She is a clinical investigator and the author or co-author of numerous journal articles, reviews, abstracts and book chapters. Some of her work has been published in the American Journal of Respiratory and Critical Care Medicine, the Journal of the American Medical Society and Chest, among others. Her current research interests focus on the diagnosis of and delivery of care to patients with COPD. She is a member and past officer of the American College of Physicians, a member of the American Thoracic Society, and a Fellow of the American College of Chest Physicians.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined by Professor Omar Usmani to discuss inhalation effort and the factors that influence drug delivery in patients with COPD. They will explain why inhaler choice is an important consideration and what patient characteristics to look out for when prescribing.1,2 Dr Russell will also delve into a newly released publication on fungal sensitisation and the impact this has on patients with COPD.3 Following this, he will highlight what people are talking about on social media regarding COVID-19 and COPD, including mask wearing and the effect of the pandemic on exacerbation rates.
1 Dekhuijzen PNR, et al. Respir Med 2013;107:1817–1821; 2 Usmani OS. Ther Clin Risk Manag 2019;15:461–472; 3 Tiew PY, et al. Eur Respir J 2020;56:2000418.
DisclosuresProfessor Omar UsmaniDr Omar Usmani reports research funding, advisory board attendance and symposium funding from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Covis, Edmond Pharma, GlaxoSmithKline, Mundipharma, Napp, Novartis, Roche, Sandoz, Takeda, Trudell Medical, UCB and Vectura..
Bios:
Professor Omar UsmaniProfessor Omar Usmani is Professor of Respiratory Medicine and Honorary Consultant Physician at the National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital and St Mary’s Hospital London. He is Head of Assembly 5 (Airway Diseases, Asthma, COPD and Chronic Cough) at the European Respiratory Society (ERS), Vice President for Scientific Outputs of the Respiratory Effectiveness Group (REG), Chair of the UK Inhaler Group (UKIG), Vice-Chair of Drug Delivery to the Lungs (DDL) and President-elect of the International Society of Aerosols in Medicine (ISAM). In 2019, he was made a Fellow of the ERS.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell and Professor Michael Dreher present the 2020 American Thoracic Society Guidelines on the management of COPD,1 to which Professor Dreher was a key contributor. Listen as the experts deliberate on the use of dual bronchodilation and inhaled corticosteroids in patients with COPD, as well as reviewing conditional and strong recommendations for treatment, according to the guidelines.1,2 Dr Russell will also discuss the findings of a publication about maintenance inhaler therapy preferences of patients with COPD.3 Finally, Dr Russell will delve into the social media hot topic of air pollution and the effects it can have on patients with COPD.
1 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e69;2 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;3 Tervonen T, et al. Thorax 2020;75:735–743
DisclosuresProfessor Michael DreherProfessor Michael Dreher reports speaker fees from Actelion Pharmaceuticals, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Hamilton, Heinen und Löwenstein, Linde, Novartis, Pfizer, Philips Respironics, ResMed, Roche and Weinmann. He also reports consulting fees from Almirall, Boehringer Ingelheim, Linde, Novartis, Pfizer, Philips Respironics, ResMed and Roche, and research grants from Linde, Philips Respironics and ResMed.
Bios:
Professor Michael DreherProfessor Michael Dreher is the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany). He is Member of the Board of Trustees of the "Deutsche Lungenstiftung“and management board member of several German societies, including the German Airway League. Prof Dreher's research interests focus on the management of chronic obstructive pulmonary disease and other lung diseases, and also include aspects of critical care medicine.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Professor Dave Singh joins Dr Richard Russell to explore the benefits of using dual bronchodilation versus monobronchodilation in patients with COPD.1 They will explain the impact of breathlessness and physical inactivity on patients,2,3 as well as what the clinical guidelines recommend in terms of initial and follow-up treatment for COPD.1,4 A new publication focusing on the long-term effects of pulmonary rehabilitation in elderly patients will be highlighted by Dr Russell,5 followed by a review of the impact of biomass fuel on COPD, a current hot topic on social media.
1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;2 Troosters T, et al. Respir Med 2010;104:1005–1011;3 Waschki B, et al. Chest 2011;140:331–342;4 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e59;5 Gephine S, et al. Int J Chron Obstruct Pulmon Dis 2020;15:2505–2514.
DisclosuresDr Richard RussellDr Richard Russell has received speaker fees from AstraZeneca, GlaxoSmithKline, Chiesi and Boehringer Ingelheim. He has also received project grant support from AstraZeneca.
Professor Dave SinghProfessor Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Teva, Theravance and Verona.
Bios:
Dr Richard RussellDr Richard Russell is a Consultant Chest Physician at Lymington New Forest Hospital (UK), as well as a Senior Clinical Researcher at the University of Oxford, and is the founding editor of the International Journal of COPD. He is also the Clinical Lead for Respiratory Medicine, Southeast England, UK, the Director of West Hampshire Integrated Respiratory Service, UK, and an Honorary Senior Lecturer at Imperial College London, UK.
Professor Dave SinghDave Singh is Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester and supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the Medical Director of the Medicines Evaluation Unit at the University of Manchester, where he has acted as principal investigator in over 300 clinical trials. He is a member of the GOLD Science Committee, and an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society, and has over 350 publications.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

In this episode of the Medical Insider COPD podcast, join Dr Richard Russell and Professor James Chalmers as they discuss the implications of the recent European Respiratory Society Guidelines on COPD patient care.1 Listen as the experts debate the use of inhaled corticosteroids and discuss who is most likely to benefit from their withdrawal. 1 Dr Russell also shares highlights from a publication about patients’ healthcare system encounters before they receive a COPD diagnosis.2 Finally, Dr Russell delves into a hot social media topic, looking at the implications that diet and nutrition can have for patients with COPD.
1. Chalmers JD, et al. Eur Respir J 2020;55:2000351;2. Johnson KM, et al. Thorax 2020;75:108–115.
DisclosuresProfessor James Chalmers
Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon
Research grant support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Insmed and Novartis
Dr Richard Russell
Dr Richard Russell has received speaker fees from AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim.
Project grant support from AstraZeneca
Funding statementThis podcast programme was developed by an independent editorial board, funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review for medical and scientific accuracy.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.